About

GENERAL INFORMATION YUMAB develops therapeutic antibodies for clients and partners using one of world’s largest human antibody libraries (>10e11), patient derived libraries or immune libraries. YUMAB's integrated discovery and engineering platform offers highest success-rates to all types of antigens including “difficult” targets such as GPCRs, transporters or ion channels. YUMAB provides all technologies from target to optimized lead in one hand. Technologies include fast track in vitro antibody selection and screening (including on cell selection), antibody engineering (including superhumanization) and bioinformatic lead optimization. Newest achievement is the fast track COVID-19 program of YUMAB's spin-off CORAT Therapeutics from target to patient in 11 months. SUMMARY PRODUCTS / SERVICES / TECHNOLOGIES 1. Fast track discovery of fully human antibodies 2. Immune or patient derived libraries (also from transgenic animals) 3. Antibody lead development (IgG, Fab, scFv, bispecifics, CAR, ADC, ...) 4. Antibody engineering (affinity, stability, manufacturability) 5. In silico lead optimization 6. Hybridoma sequencing 7. Humanization, Superhumanization 8. Contract research and development 9. Partnered development About YUMAB GmbH GENERAL INFORMATION YUMAB develops therapeutic antibodies for clients and partners using one of world’s largest human antibody libraries (>10e11), patient derived libraries or immune libraries. YUMAB's integrated discovery and engineering platform offers highest success-rates to all types of antigens including “difficult” targets such as GPCRs, transporters or ion channels. YUMAB provides all technologies from target to optimized lead in one hand. Technologies include fast track in vitro antibody selection and screening (including on cell selection), antibody engineering (including superhumanization) and bioinformatic lead optimization. Newest achievement is the fast track COVID-19 program of YUMAB's spin-off CORAT Therapeutics from target to patient in 11 months. SUMMARY PRODUCTS / SERVICES / TECHNOLOGIES 1. Fast track discovery of fully human antibodies 2. Immune or patient derived libraries (also from transgenic animals) 3. Antibody lead development (IgG, Fab, scFv, bispecifics, CAR, ADC, ...) 4. Antibody engineering (affinity, stability, manufacturability) 5. In silico lead optimization 6. Hybridoma sequencing 7. Humanization, Superhumanization 8. Contract research and development 9. Partnered development About YUMAB GmbH YUMAB is an innovative biotech company developing next-generation therapeutic antibodies for clients and partners worldwide. The YUMAB platform comprises proprietary library technologies including one of the world’s largest human antibody libraries (>10e11), patient derived libraries and immune libraries from many different species. YUMAB integrates all technologies from discovery over engineering and AI enabled lead optimization to achieve highest success-rates to all types of targets, modalities and indications, e.g. for the development of TCRm to pHLA. YUMAB also offer licenses to its antibody technology platforms such as a novel BBB shuttle technology or T cell engagers.